ReviewReviews in endocrine & metabolic disorders2021
Laron syndrome - A historical perspective.
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- The genetics of obesity: aetiology, prevention and therapy.Nature metabolism · 2026Review
- The 20 kDa isoform of the human growth hormone variant alters adipose and muscle gene expression differently than human growth hormone.Journal of neuroendocrinology · 2025Article
- Disabilities and Handicaps of Patients with Laron Syndrome.Children (Basel, Switzerland) · 2025Article
- Vascular smooth muscle cell-specific Igf1r deficiency exacerbates the development of hypertension-induced cerebral microhemorrhages and gait defects.GeroScience · 2024Article
- Trends of correlations between serum levels of growth hormone and insulin-like growth factor-I in general practice.Frontiers in endocrinology · 2024Article
- Clinical characteristics and treatment efficacy in patients with primary severe IGF-1 deficiency treated with recombinant IGF-1.Frontiers in pediatrics · 2024Article
- Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden.Frontiers in endocrinology · 2024Article
- Growth hormone insensitivity and adipose tissue: tissue morphology and transcriptome analyses in pigs and humans.Pituitary · 2023Article
- Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective.Orphanet journal of rare diseases · 2023Review
- Clinical characteristics and genetic expansion of 46,XY disorders of sex development children in a Chinese prospective study.Endocrine connections · 2023Article
- High growth hormone serum partially protects mice against Trypanosoma cruzi infection.FEBS open bio · 2023Article
- Divergent metabolic phenotypes in two genetic syndromes of low insulin secretion.Diabetes research and clinical practice · 2023Article
- Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment.Stem cell reviews and reports · 2023Article
- Decreased IGF1R attenuates senescence and improves function in pancreatic β-cells.Frontiers in endocrinology · 2023Article
- Short stature related to Growth Hormone Insensitivity (GHI) in childhood.Frontiers in endocrinology · 2023Review
- The Multiple Functions of Insulin Put into Perspective: From Growth to Metabolism, and from Well-Being to Disease.International journal of molecular sciences · 2022Article
- The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC.Cell reports · 2022Article
- The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target.Life (Basel, Switzerland) · 2022Review
- First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model.Gene therapy · 2022Article
- Physical Examination for Endocrine Diseases: Does It Still Play a Role?Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laron Syndrome (LS) [OMIm#262500], or primary GH insensitivity, was first described in 1966 in consanguineous Jewish families from Yemen. LS is characterized by a typical phenotype that includes dwarfism, obesity and hypogenitalism. The disease is caused by deletions or mutations of the GH-receptor gene, causing high serum GH and low IGF-I serum levels. We studied 75 patients from childhood to adult age. After early hypoglycemia due to the progressive obesity, patients tend to develop glucose intolerance and diabetes. The treatment is by recombinant IGF-I, which improves the height and restores some of the metabolic parameters. An unexpected finding was that patients homozygous for GH-R defects are protected from malignancy lifelong, not so heterozygotes or double heterozygote subjects. We estimate that there are at least 500 patients worldwide, unfortunately only few treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.